Versa

Quick links to important sections

Versa

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Versa

What is Versa? A Short-Acting Sedative Overview

Property Description
Active Ingredient Midazolam hydrochloride
Pharmacological Class Benzodiazepine / CNS Depressant
Common Use Procedural Sedation, Acute Seizure Termination
Origin Synthetic
Key Property Rapid Onset, Short Duration of Action

What Type of Medicine is Versa (Midazolam)?

Versa is a brand name for the generic medicine Midazolam, a synthetic pharmaceutical agent classified as an Imidazobenzodiazepine, belonging to the larger Benzodiazepine class. It is primarily classified as a powerful, fast-acting Central Nervous System (CNS) depressant.

The drug’s core identity is defined by its rapid action. Its chemical profile is clinically recognized for ensuring rapid onset and a short duration of effect, a differentiating factor from older, longer-acting analogues. The active component, Midazolam hydrochloride, is formulated to be water-soluble in solution, which is advantageous for its preparation and reliable parenteral administration. The drug's general purpose is strictly defined by its pharmacological effect: to safely and quickly induce a state of profound calm and reduced awareness for time-sensitive medical requirements.


Composition, Forms, and General Purpose

The medication is a single-ingredient product, containing Midazolam hydrochloride as its sole active compound, and is an Essential Medicine. It is available in various high-level pharmaceutical preparations, including a sterile Aqueous Solution for injection, and non-invasive formats like an Oral Syrup, Nasal Spray, and a Buccal Solution.

These diverse forms facilitate multiple routes of administration, enabling rapid action even when traditional intravenous access is impractical. The ultimate purpose of Midazolam is to provide temporary central nervous system control, inducing deep sedation, relief from anxiety (anxiolysis), and temporary loss of memory (anterograde amnesia) for procedural or emergency needs.

Regulatory References

  1. Midazolam - StatPearls - NCBI Bookshelf

What side effects are possible with Versa?

Possible Side Effects and Safety Information

The official safety profile of Versa (Midazolam) is primarily defined by its effects as a powerful Central Nervous System (CNS) depressant. Adverse reactions are classified by regulatory agencies, primarily focusing on cardiorespiratory, neurological, and psychiatric systems.

Serious Adverse Reactions

The most serious documented risk involves the cardiorespiratory system, including respiratory depression, apnea, and cardiac arrest. These severe events have been documented, sometimes leading to death or permanent neurologic injury, particularly following rapid administration. Profound sedation is also a serious risk, especially when Versa is used concomitantly with other CNS depressants like opioids, a combination noted in regulatory warnings to increase the risk of coma and death.

Common and System-Based Effects

Adverse effects are grouped into System-Organ-Classes (SOC) in official documentation. Nervous System Disorders are frequently affected, with high-incidence reactions including somnolence (drowsiness), headache, and anterograde amnesia (impaired recall). Reactions such as nausea and vomiting fall under Gastrointestinal Disorders. Paradoxical reactions, including agitation or involuntary movements, are also documented within psychiatric disorders.

Population and Duration Safety Patterns

Certain groups face explicit safety considerations. Older adults and those with existing cardiorespiratory or hepatic/renal impairment are documented as being more sensitive to respiratory depressant effects and may experience prolonged drug effects. Furthermore, use extending over several days to weeks carries the official risk of developing physical dependence and a subsequent withdrawal syndrome upon abrupt discontinuation. Safety-related limitations define conditions like severe hepatic impairment and acute narrow-angle glaucoma where use is constrained or contra-indicated.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Versa (risperidone) typically presents as an exaggeration of its known pharmacological effects, according to regulatory documents. These manifestations primarily involve the central nervous system (CNS) and the cardiovascular system.

Key documented symptoms include drowsiness, sedation, tachycardia (rapid heart rate), hypotension (low blood pressure), and extrapyramidal symptoms (involuntary muscle movements). More severe, potentially life-threatening risks reported in overdose situations include a prolonged QT interval—a serious cardiac change—and convulsions (seizures). Cases of accidental overdose, particularly with the oral solution in children and adolescents, have been reviewed by regulatory bodies.

Required Emergency Action

Immediate medical help must be sought for any suspected overdose. Emergency services (911 or local equivalent) should be called immediately if the person has collapsed, experiences a seizure, has trouble breathing, or cannot be awakened.

Treatment is symptomatic and supportive, focusing on ensuring an adequate airway, oxygenation, and ventilation. Medical personnel will closely monitor cardiac rhythm, vital signs, and provide supportive care, which may include the use of intravenous fluids for hypotension. The possibility of overdose involving multiple substances must always be considered by healthcare providers.

Therapeutic Uses of Versa

What Versa Treats: Main Uses and Benefits

The primary role of Versa is to provide short-term support for managing noticeable symptomatic discomfort and supporting a sense of functional stability. The medicine is generally applied across domains where additional symptomatic assistance is needed, such as in situations involving distressing symptoms.

Easing Periods of Heightened Discomfort

Versa is applied in general clinical scenarios when symptoms intensify and supportive relief is needed, such as during phases of increased distress or discomfort. The medication may help in addressing this physiological strain and contributes to easing the overall symptom load during periods marked by heightened symptoms. The therapeutic use may be relevant for conditions where functional stability becomes affected, episodic or fluctuating manifestations, and acute or disruptive episodes.

“It supports patients during difficult episodes, assisting with functional stability.”

Supporting Symptoms that Cluster Together

This medicine is commonly used for managing symptom clusters that may become disruptive and interfere with daily comfort. It is relevant for easing distress, supporting general well-being, and is applied when symptoms create noticeable physiological strain.

Quick Fact: Support During Acute Episodes Versa may be considered relevant when symptoms become temporarily overwhelming.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Versa is a hyaluronic acid dermal filler used for facial aesthetic procedures. It is generally intended for adults aged 22 and older who wish to temporarily correct facial wrinkles and folds.


Contraindications (Who Cannot Use Versa)

Treatment with Versa is not recommended for individuals with certain medical conditions or circumstances. It is contraindicated in patients with:

  • A known history of severe allergies (anaphylaxis) or multiple severe allergies, especially those with heightened immune responses to common allergens (atopy).
  • Documented allergies to hyaluronic acid, Gram-positive bacterial proteins, or lidocaine (as the product contains it).
  • Skin infections (acute or chronic) or unhealed wounds in or near the intended treatment area, including conditions like active acne, psoriasis, or rosacea.
  • A tendency toward hypertrophic scarring or keloid formation, or evidence of scars at the proposed injection sites.
  • Pregnancy or breastfeeding, as the safety of the product in these populations has not been established.

Precautions

Caution is advised for patients undergoing anticoagulant or antiplatelet therapy, or those with a history of bleeding disorders, as these conditions can increase the risk of bruising and bleeding at the injection site. It is also recommended to wait at least four weeks after receiving certain other facial treatments, such as chemical peels or laser therapy, before receiving Versa.

What should I know about interactions with other medicines?

Versa Interactions with other medicines and products

Versa is involved in multiple pharmacokinetic and pharmacodynamic interactions as documented in official regulatory labeling. These interactions can significantly modify the concentration of Versa in the bloodstream or affect the combined action of co-administered medicines.

Pharmacokinetic Interactions

Versa is primarily a substrate of the enzyme CYP3A4 and the transporter P-glycoprotein (P-gp). Therefore, co-administration with strong inhibitors of these systems (e.g., ketoconazole, clarithromycin) increases Versa exposure, a classification of clinically significant interaction. Conversely, strong CYP3A4 inducers (e.g., rifampin, St. John's Wort) are contraindicated because they can substantially decrease Versa concentrations, leading to a loss of therapeutic effect. Versa itself is documented as an inhibitor of OATP1B1 and OATP1B3 transporters, necessitating monitoring or dose adjustment for sensitive co-administered substrates, such as certain statins (e.g., rosuvastatin).

Pharmacodynamic and Substance Interactions

Official labeling warns of additive pharmacodynamic effects when Versa is co-administered with other medicines known to prolong the QT interval or cause bradycardia. Regarding non-medicinal substances, the label notes that a high-fat meal may increase Versa exposure. Furthermore, administration requires temporal separation: Versa should be taken at least 2 hours before or 4 hours after polyvalent cation-containing substances, such as aluminum- or magnesium-containing antacids, to avoid reduced absorption. Interaction risks may be exaggerated in patients with hepatic impairment.

Mechanism of Action

Modulating Core Receptor and Enzyme Systems

Versa initiates its action at the molecular level through selective binding to specific receptor or enzyme systems within target cells. This interaction is characterized by a precise modulation of activity, functioning either to initiate or block signal transduction. By focusing its effect on these key regulatory proteins, Versa establishes its domain of action over processes that govern signal flow in defined pathways.


Targeted Regulation of Signaling Pathways

The drug operates within defined molecular cascades, altering the dynamics of neural or humoral pathways immediately following the primary binding event. This mechanistic interference contributes to the modulation of signaling within overactive pathways and adjusts the rate of signal propagation. Versa's influence drives the targeted pathways toward altered activity levels and is relevant in systems where specific transmitters or mediators dominate the signaling process.


Modifying Dysregulated Physiological Activity

The overall consequence of Versa's mechanism is the adjustment of an imbalanced state within the affected biological system. By influencing core regulatory mechanisms, the drug modifies the effect of dysregulated mediators or systems, resulting in an alteration of downstream pathway activity. This influence drives the resulting modification in biological system function without leading to an outright termination of the original pathway activity.

Dosage and Administration Information

How to Use Versa: Administration Guidelines

Versa (Midazolam) is administered according to established protocols that define its route, dose, and required procedural context. The medicine is designated for short-term or acute use and is not intended for chronic daily therapy.

Administration Scope Description
Route of administration Intravenous (IV), Intramuscular (IM), Oral, and Nasal (for specific forms and uses).
Dosing schedule Titration to effect for IV procedural use (initial doses typically 1 mg to 2.5 mg); weight-based single dose for IM premedication; fixed single dose for acute seizure termination.
Age-group administration rules Older adults require a reduced initial dose (often 20% to 50% lower) and slower titration; pediatric doses are typically based on weight (mg/kg).

Procedural Constraints and Frequency

The frequency pattern is as-needed (PRN) or single-use only. For IV sedation, the administration is an intermittent process where subsequent doses are given only after a waiting interval of two to three minutes to assess the patient’s response. This slow titration and the mandatory requirement for continuous monitoring in a setting with resuscitation capability are explicit procedural conditions. This protocol structure ensures the medicine is used only for brief, acute events and mandates strict control over administration rate and dose adjustment, particularly for sensitive populations.

Recent Clinical Evidence

Overview of Research Evidence for Versa (Midazolam)

The research evidence for Versa is compiled primarily from clinical trials and scientific literature reviewed by regulatory bodies. Studies have focused on examining how the medicine was observed in specific, time-sensitive medical situations, where the research explores outcomes related to rapidly achieving a temporary change in awareness. This overview summarizes the structure of that evidence, detailing the types of research conducted and the areas where information remains limited.


Evidence for Use in Procedural Sedation and Anxiolysis

Research has focused on exploring Versa's role in the context of procedural sedation, examining measures related to anxiety for patients undergoing brief procedures, such as diagnostic testing or minor surgery.

Researchers utilized Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews. Trials measured the level of sedation achieved using standardized scales, documented measures related to anxiety before procedures, and quantified the onset of anterograde amnesia (temporary inability to form new memories). Study populations included adults across a wide range of ages, as well as children (pediatrics).

Studies reported measurements of onset time for the assessed sedation and amnesia endpoints, typically documented within minutes of administration. The reported recovery time was frequently documented, reflecting the specific time intervals over which discharge criteria were evaluated.


Evidence for Use in Acute Seizure Termination

Research primarily consisted of Randomized Controlled Trials (RCTs) conducted in pre-hospital or emergency settings. These studies focused on comparing different non-intravenous routes of administration (such as buccal or nasal delivery) against established treatments. This research examined measures used to assess the outcome, such as the time required for seizure cessation.

Across multiple clinical trials, studies reported the measured time to cessation of convulsive activity. Studies monitored how symptoms evolved in the observed populations, describing patterns related to the termination of acute seizures in the observed populations. The relationship between the observed duration of effect and the potential for seizure recurrence is a recurring topic in the scientific literature.


What Remains Under Study or Uncertain

Research on Versa contributes to the broader evidence landscape, but certainty remains low in several areas. Limited information is available regarding the long-term functional consequences or outcomes following repeated exposure, as the follow-up durations were limited in the primary trials. Evidence quality varies across studies when comparing Versa directly against certain newer or less-common alternative treatments. Subgroup findings, particularly for specific comorbidities, are often uncertain because sample sizes were modest or the populations were narrowly defined in initial studies. Research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Midazolam - StatPearls - NCBI Bookshelf (Review of Indications and Evidence)

Frequently Asked Questions (FAQ)

Common questions about Versa (FAQ)


Q: What happens if I forget to take Versa?

A: Regulatory documents define Versa for short-term, acute use and administration on an as-needed (PRN) basis. The approved usage pattern is for managing specific, time-sensitive medical situations. Therefore, the concept of a regularly scheduled dose to be 'forgotten' does not apply to its approved conditions of use.

Q: What is the difference between Versa and its active ingredient?

A: Versa is the brand name under which the active ingredient, midazolam, is made available. Official regulatory documentation, including safety and efficacy data, refers primarily to the properties of the active ingredient, midazolam.

Q: Are there any specific foods or drinks to avoid while using Versa?

A: Official labeling explicitly warns against consuming alcohol while using the medicine, as this can significantly increase the drug's sedative effects. Official labeling indicates that consuming grapefruit or grapefruit juice may also affect the metabolism of the drug and increase its exposure in the body.

Q: Is it possible for Versa to lose its effectiveness over time?

A: Official warnings note that the use of this medicine extending over several days to weeks carries the risk of developing physical dependence. This risk is associated with an altered response to the drug and the possibility of a withdrawal syndrome if discontinued abruptly.

Q: Can Versa affect fertility or pregnancy planning?

A: Studies examined the effects on fertility and did not find an impairment according to regulatory findings. However, use during pregnancy is associated with potential risks to the fetus, and use during this period is a factor that is noted to require specific consideration and monitoring.

Q: Are the side effects of Versa permanent?

A: Common effects like drowsiness are typically temporary, which is consistent with the drug’s relatively short elimination half-life (the time required for drug levels to decrease by half). However, official safety warnings do note that certain serious adverse events involving the cardiorespiratory system may lead to permanent injury.

Q: Does the time of day I take Versa matter?

A: Regulatory information indicates the drug is defined for acute, as-needed use to manage time-sensitive medical events. Its use is procedural, meaning it is administered when needed for a brief event, and is not a daily regimen tied to a specific time of day.

Q: Are there any black box warnings associated with Versa?

A: Official regulatory documents include a Boxed Warning that highlights significant risks. This warning cautions about the risks of profound sedation, respiratory depression, coma, and death, particularly when used concurrently with opioids or other central nervous system depressants.

Q: What is the recommended storage temperature for Versa?

A: Official labeling indicates that the medicine should be stored at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F). The labeling specifies preventing the product from freezing and maintaining it within the defined temperature range.

Q: What is the maximum duration of treatment with Versa that has been studied?

A: The drug is officially designated for short-term or acute use. Official warnings caution against use extending over several days to weeks, as this is associated with the risk of developing physical dependence and a subsequent withdrawal syndrome upon discontinuation.

Q: Does Versa affect blood pressure?

A: Regulatory documents note that the drug can affect the cardiorespiratory system, with administration carrying the risk of cardiac arrest. Administration may also be associated with prolonged hypotension, which is a regulatory term for low blood pressure.

Q: Is Versa metabolized by the liver?

A: Official documentation states that the drug is primarily processed in the body by liver enzymes. Specifically, the medicine is a substrate of the CYP3A4 enzyme system.

Q: How long does Versa stay in the body after the last use?

A: Regulatory data states the drug's elimination half-life in healthy adults is typically in the range of 1.8 to 6.4 hours. This half-life is the time required for the concentration of the medicine in the body to be reduced by half.

Q: Is Versa available in different strengths?

A: Regulatory information indicates the medicine is made available in several formulations and strengths. These may include different concentrations for injection, oral solutions, or specific tablet strengths, depending on the route of administration.

Q: What is the official classification of Versa (e.g., antibiotic, antidepressant, etc.)?

A: According to official product information, the medicine belongs to the drug class known as Benzodiazepines.

Q: Are there specific genetic factors that affect how Versa works?

A: The drug's metabolism is dependent on the CYP3A4 enzyme system, which is a key focus of regulatory warnings concerning drug interactions. This enzyme system can be influenced by individual genetic makeup, suggesting potential variability in drug processing.

Q: Can Versa be used if I have a history of heart issues?

A: Regulatory documentation lists cardiovascular risk as a precaution. Use may involve specialized monitoring of the cardiovascular and respiratory systems, and the risk of adverse effects may be elevated in patients with existing heart conditions.

Q: Does alcohol change the way Versa works?

A: Official labeling explicitly warns against consuming alcohol while using the medicine. Alcohol may significantly increase the depressant effects of the drug, leading to enhanced symptoms such as drowsiness and dizziness.

Q: Is Versa available in a generic version?

A: The active ingredient in Versa, midazolam, is available as a generic medication.

Q: Does Versa interact with common over-the-counter pain relievers?

A: Official information notes that the drug can interact with other central nervous system depressants. This may include components found in certain over-the-counter medicines, which could potentially result in an increased risk of sedation.

Q: Can Versa interfere with birth control pills?

A: The medicine is processed by the CYP3A4 enzyme system. Official documents note that certain types of birth control pills may affect this system, which could potentially prolong the half-life and duration of action of the drug.

Q: Does Versa require any special testing before starting treatment?

A: While routine blood testing is not generally cited as a prerequisite, the highly controlled nature of its use is noted. The drug must only be administered in settings capable of providing continuous monitoring of respiratory and cardiac function.

Q: Is Versa safe to take while breastfeeding?

A: Regulatory documents state that the medicine is excreted into human milk. Because of this, use during this period is noted to involve specific considerations, and the infant's response should be monitored for potential effects like sedation or poor feeding.

Q: Do lifestyle changes affect the outcome of using Versa?

A: The drug’s official labeling notes that certain dietary factors can influence how the body handles the medicine. For instance, consuming a high-fat meal or grapefruit products may affect the drug's exposure in the bloodstream.

Q: Is Versa a controlled substance?

A: The medicine is classified in the United States as a Schedule IV controlled substance. This legal status recognizes accepted medical use but indicates a potential for abuse and dependence.

How should Versa be stored and disposed of?

Storage and Protection Requirements

Versa (Midazolam Injection) must be stored and handled according to specific official requirements to maintain its integrity and comply with controlled substance regulations.

Detail Official Regulatory Requirement
Storage Temperature Store at Controlled Room Temperature, 20 to 25 C (68 to 77 F).
Environmental Protection Must be protected from light and stored in its original outer carton. The product should not be frozen.
Child Safety/Security As a controlled substance, it must be stored securely (e.g., locked up) and kept out of the sight and reach of children and pets.

Disposal Instructions

Official disposal is governed by controlled substance and environmental regulations:

  • Single-Dose Vials: Any unused portion remaining in a single-dose vial must be discarded immediately after use.
  • Unused Product: Disposal of the product and container must adhere to local, regional, and national regulations. Patients should follow drug take-back programs when available.
  • Environmental Caution: The product must not be allowed to enter sewers or surface water.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Versa found in:

A-Z Index: